Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients

PURPOSE: Radionuclide therapy with (177)Lu-DOTATATE is well established for patients with advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule of 7.4 GBq at four occasions. However, this approach does not consider individual variability affecting the tumor radiation...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundlöv, Anna, Gleisner, Katarina Sjögreen, Tennvall, Jan, Ljungberg, Michael, Warfvinge, Carl Fredrik, Holgersson, Kajsa, Hallqvist, Andreas, Bernhardt, Peter, Svensson, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399027/
https://www.ncbi.nlm.nih.gov/pubmed/35451612
http://dx.doi.org/10.1007/s00259-022-05786-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399027/
https://www.ncbi.nlm.nih.gov/pubmed/35451612
http://dx.doi.org/10.1007/s00259-022-05786-w

Ejemplares similares